Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

NCT07016750 is registered in ClinicalTrials.gov with Krystal Biotech, Inc. as lead sponsor.

NCT NCT07016750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07016750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
Lead sponsor
Krystal Biotech, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 20, 2025
Completion date
December 31, 2026
Enrollment
16 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

deb - dystrophic epidermolysis bullosa, dominant dystrophic epidermolysis bullosa, dystrophic epidermolysis bullosa, recessive dystrophic epidermolysis bullosa